Literature DB >> 10432379

Genetic mapping of modifier loci affecting malignant hypertension in TGRmRen2 rats.

S Kantachuvesiri1, C S Haley, S Fleming, K Kurian, C E Whitworth, P Wenham, Y Kotelevtsev, J J Mullins.   

Abstract

BACKGROUND: Genetic background has a major influence on the manifestation of multifactorial diseases such as hypertension in which severe complications may be caused through an interaction with additional factors, which may be genetically determined. We have previously described a genetic model of malignant hypertension (MH) in rats carrying the mouse Ren2 gene (TGRmRen2-27), in which the phenotype is dependent on the genetic background.
METHODS: Using a single homozygous TGRmRen2-27 male as transgene donor, we produced two F1 populations with (a) 100% penetrance of MH in progeny heterozygous for the Fischer F344 genetic background and (b) 58.5% penetrance in progeny heterozygous for the Lewis genetic background. To identify the modifier loci affecting the phenotype, a cohort of 252 males was produced by breeding the same single male with Fischer-Lewis F1 females. The progeny were phenotyped for clinical and pathological features of MH.
RESULTS: Genome-wide screening and quantitative trait loci (QTL) analysis identified two loci, on chromosome 10 (LOD 4.4) and on chromosome 17 (LOD 3.9) close to the Ace and At1 genes, respectively, which contribute to the lethal MH phenotype. Their influence on mortality was consistent with a multiplicative effect of the two loci. In addition, we found higher plasma angiotensin-converting enzyme activity in progeny receiving the Fischer allele than in progeny receiving the Lewis allele (123.5 +/- 9.5 vs. 91.8 +/- 4.9 U/liter, P < 0.01), suggesting the association of angiotensin-converting enzyme and MH.
CONCLUSIONS: Our study demonstrates the application of a transgene as a "major gene" to facilitate the identification of modifier loci, which can affect the phenotype of MH, and reveals Ace and At1 as candidate genes involved in the manifestation of the MH phenotype.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10432379     DOI: 10.1046/j.1523-1755.1999.00571.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  15 in total

1.  Enhanced urinary angiotensinogen excretion in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension.

Authors:  Carlo J Milani; Hiroyuki Kobori; John J Mullins; Kenneth D Mitchell
Journal:  Am J Med Sci       Date:  2010-11       Impact factor: 2.378

2.  Standing genetic variation and compensatory evolution in transgenic organisms: a growth-enhanced salmon simulation.

Authors:  Robert N M Ahrens; Robert H Devlin
Journal:  Transgenic Res       Date:  2010-09-29       Impact factor: 2.788

3.  Transient induction of ANG II-dependent malignant hypertension causes sustained elevation of blood pressure and augmentation of the pressor response to ANG II in CYP1A1-REN2 transgenic rats.

Authors:  Catherine G Howard; John J Mullins; Kenneth D Mitchell
Journal:  Am J Med Sci       Date:  2010-06       Impact factor: 2.378

4.  Imatinib ameliorates renal morphological changes in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension.

Authors:  Miguel L Graciano; Kenneth D Mitchell
Journal:  Am J Physiol Renal Physiol       Date:  2011-10-05

5.  Association of the D allele of the angiotensin I converting enzyme polymorphism with malignant vascular injury.

Authors:  N J Mayer; A Forsyth; S Kantachuvesiri; J J Mullins; S Fleming
Journal:  Mol Pathol       Date:  2002-02

6.  Angiotensin-converting enzyme is a modifier of hypertensive end organ damage.

Authors:  Xiaojun Liu; Christopher O C Bellamy; Matthew A Bailey; Linda J Mullins; Donald R Dunbar; Christopher J Kenyon; Gillian Brooker; Surasak Kantachuvesiri; Klio Maratou; Ali Ashek; Allan F Clark; Stewart Fleming; John J Mullins
Journal:  J Biol Chem       Date:  2009-03-23       Impact factor: 5.157

Review 7.  Vascular injury in systemic sclerosis: angiotensin-converting enzyme insertion/deletion polymorphism.

Authors:  Cinzia Fatini; Serena Guiducci; Rosanna Abbate; Marco Matucci-Cerinic
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

8.  Increased sympathetic drive during the onset of hypertension in conscious Cyp1a1-Ren2 rats.

Authors:  Su Young Han; Emily Gray; Gillian Hughes; Colin H Brown; Daryl O Schwenke
Journal:  Pflugers Arch       Date:  2013-08-25       Impact factor: 3.657

9.  Angiotensin-converting enzyme i/d polymorphism in patients with malignant hypertension.

Authors:  Eugenia Espinel; Jose Luis Tovar; Javier Borrellas; Luis Piera; Rosendo Jardi; Francisco Rodriguez Frias; Luis Armadans; Ana Gonzalez Bachs
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-01       Impact factor: 3.738

Review 10.  Towards Precision Medicine for Hypertension: A Review of Genomic, Epigenomic, and Microbiomic Effects on Blood Pressure in Experimental Rat Models and Humans.

Authors:  Sandosh Padmanabhan; Bina Joe
Journal:  Physiol Rev       Date:  2017-10-01       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.